MedPath

FDA Revokes Emergency Use Authorization for Bebtelovimab Due to Expired Lots and Variant Resistance

• The FDA revoked the Emergency Use Authorization (EUA) for bebtelovimab on December 5, 2024, following a request from Lilly due to the expiration of all manufactured lots. • Bebtelovimab was no longer authorized for use in regions where SARS-CoV-2 variants demonstrated resistance, based on available susceptibility data and variant frequency. • The FDA determined that revoking the EUA was necessary to protect public health, given the reduced efficacy against circulating variants and the expiration of existing supplies.

The U.S. Food and Drug Administration (FDA) has revoked the Emergency Use Authorization (EUA) for bebtelovimab, a monoclonal antibody previously authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients. The decision, announced on December 13, 2024, follows a request from Eli Lilly and Company, the manufacturer of bebtelovimab.
Lilly's request stemmed from the expiration of all bebtelovimab lots manufactured and labeled under EUA 111. Furthermore, the drug was no longer authorized for use in geographic regions of the United States where infection was likely caused by non-susceptible SARS-CoV-2 variants. This determination was based on available information, including variant susceptibility to bebtelovimab and regional variant frequency.
The FDA concluded that revoking the EUA was appropriate to protect public health and safety. The agency's decision reflects concerns about the drug's effectiveness against emerging variants and the practical limitations of using expired medication.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Revokes Emergency Use Authorization for Sotrovimab

The FDA has revoked the Emergency Use Authorization (EUA) for sotrovimab due to the expiration of all manufactured lots under EUA 100.
GSK requested the EUA revocation on November 22, 2024, as sotrovimab was not authorized for use against non-susceptible SARS-CoV-2 variants.

FDA Revokes Emergency Use Authorizations for COVID-19 Antibody Treatments Evusheld and REGEN-COV

The FDA has revoked the Emergency Use Authorization (EUA) for AstraZeneca's Evusheld due to the expiration of all distributed lots and high prevalence of non-susceptible variants.
Regeneron requested the FDA revoke the EUA for REGEN-COV because all manufactured lots have expired, and the company no longer intends to offer the product in the United States.

FDA Revokes Emergency Use Authorizations for Four COVID-19 Monoclonal Antibody Products

The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody products used in the U.S. government's COVID-19 response.
The revoked EUAs include treatments from Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron Pharmaceuticals due to the rise of resistant SARS-CoV-2 variants.

FDA Revokes Authorization of GSK and Vir's Sotrovimab Due to BA.2 Inefficacy

The FDA has fully revoked the emergency use authorization for GlaxoSmithKline and Vir Biotechnology's sotrovimab due to its reduced efficacy against the Omicron sub-variant BA.2.
Sotrovimab initially received EUA based on Phase III trial data showing an 85% reduction in hospitalization or death risk for high-risk COVID-19 patients.

FDA Revokes Emergency Use Authorizations for Four Monoclonal Antibody Treatments Due to Variant Resistance

The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody (mAb) products previously used to treat COVID-19 due to persistent resistance from circulating SARS-CoV-2 variants.
These mAbs have not been authorized for patient administration for over a year because of the high prevalence of SARS-CoV-2 variants against which they are ineffective.

FDA Revokes Emergency Use Authorization for Evusheld Due to Variant Ineffectiveness

The FDA has revoked the emergency use authorization for Evusheld (tixagevimab/cilgavimab) in the U.S. due to its reduced efficacy against emerging SARS-CoV-2 variants.
Recent data indicates that Evusheld is unlikely to be effective against current dominant variants, such as XBB.1.5, which account for the majority of new infections.

FDA Withdraws Original COVID-19 Vaccine Authorization, Focuses on Bivalent Boosters

The FDA has withdrawn the emergency use authorizations for the original Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines.
Updated bivalent vaccines targeting original and Omicron BA.4/BA.5 strains are now authorized for all doses in individuals six months and older.

FDA Revokes Emergency Use Authorization for Bebtelovimab

The FDA revoked the Emergency Use Authorization (EUA) for bebtelovimab 175mg on November 30, 2022, due to its diminished efficacy against emerging COVID-19 variants.
Bebtelovimab, a monoclonal antibody infusion treatment developed by Eli Lilly, was previously authorized for treating mild-to-moderate COVID-19 in certain high-risk patients.

FDA Restricts Sotrovimab Use Due to Omicron BA.2 Variant Resistance

The FDA has suspended the authorization of GlaxoSmithKline and Vir Biotechnology's sotrovimab in regions where the Omicron BA.2 subvariant is dominant, citing inefficacy.
Sotrovimab, a monoclonal antibody, was previously authorized for treating high-risk COVID-19 patients but shows reduced effectiveness against the BA.2 subvariant.

FDA Revokes Emergency Use Authorization for Bamlanivimab Monotherapy Against COVID-19

The FDA revoked the EUA for bamlanivimab monotherapy due to increasing SARS-CoV-2 variants resistant to the treatment, raising the risk of treatment failure.
Data from the CDC showed a significant increase in resistant variants, from 5% in mid-January to approximately 20% in mid-March 2021.

Reference News

[1]
FDA Revokes Emergency Use Authorization (EUA) for Bebtelovimab for the Treatment of COVID-19
drugs.com · Apr 9, 2025

FDA revoked the Emergency Use Authorization for bebtelovimab on December 5, 2024, as all lots expired and it was not aut...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy